This page shows the latest Emergent BioSolutions news and features for those working in and with pharma, biotech and healthcare.
The US Food and Drug Administration's (FDA’s) panel of advisors has unanimously voted in favour of an over-the-counter (OTC) version of Emergent BioSolutions’ opioid overdose-reversing drug. ... Paul Williams, senior vice president and products
One need look no further than the aforementioned tragedy at Emergent BioSolutions which resulted in those 15 million Johnson and Johnson doses being tossed in the garbage. ... Apparently, it has been known for well over a year that Emergent BioSolutions
In a statement, the FDA announced that it recently completed an inspection of a proposed manufacturing site for J&J’s COVID-19 vaccine in Baltimore, operated by Emergent BioSolutions. ... Emergent BioSolutions has now paused new production of the J&J
Follows initial deal agreed in June. US-based CDMO Emergent BioSolutions has agreed a deal with AstraZeneca to expand manufacturing of the latter's potential COVID-19 vaccine. ... According to Emergent, the deal is valued at approximately $174m and runs
In the meantime the company has also announced a product divestment - selling its anthrax prevention drug raxibacumab to Emergent BioSolutions for around $96m. ... The FDA-approved therapy is tied to a $130m supply deal with the US government, which will
More recently it was revealed this week that will be working with Emergent BioSolutions on a phase I trial that would addd that firm's Ebola vaccine candidate as a booster
More from news
Approximately 2 fully matching, plus 6 partially matching documents found.
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
60. Bracco Diagnostics/ Emergent BioSolutions. Asset purchase. Healthcare Protective Products Division.
But it doesn't stop the contagious form acquired by adults. So we are working with Emergent BioSolutions and Aeras, a non-profit product developer, as well as institutions in the
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Labinger has nearly three decades of pharmaceutical and biotech industry experience, with roles at Emergent BioSolutions, Human Genome Sciences, 3M Pharmaceuticals and Immunex. ... Labinger most recently served as executive vice president and president,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...